Skip Navigation

Cardiovascular Research 1999 43(1):165-172; doi:10.1016/S0008-6363(99)00111-X
© 1999 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lamparter, S.
Right arrow Articles by Weber, K. T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lamparter, S.
Right arrow Articles by Weber, K. T
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1999, European Society of Cardiology

Angiotensin II receptor blockade during gestation attenuates collagen formation in the developing rat heart

Steffen Lamparter, Yao Sun and Karl T Weber*

Division of Cardiology, Department of Internal Medicine, University of Missouri Health Sciences Center, Columbia, MS, USA

* Corresponding author. Tel.: +1-573-882-8580; fax: +1-573-884-4691 karl_t_weber{at}muccmail.missouri.edu

Objective: Fetal cardiac development includes rapid formation of a three-dimensional collagen network, composed mainly of type I and III fibrillar collagens. Collagen fibrils have been found in cardiac jelly at very early stages of cardiac development and are thought to have structural and functional properties. In adult rat cardiac tissue, angiotensin II (AngII) via AT1 receptor binding and AngII-regulated expression of transforming growth factor beta-1 (TGF-β1) each upregulate collagen transcription. AT1 and AT2 receptor subtypes are developmentally regulated; both have been localized in fetal tissue where the AT2 receptor is considered a determinant of morphogenesis. We sought to determine whether blockade of either receptor would result in attenuation of collagen mRNA expression and fibrillar collagen accumulation and alter TGF-β1 mRNA expression in the developing fetal heart examined at birth. Methods: Pregnant rats were treated either with an AT1 receptor antagonist losartan or an AT2 receptor antagonist PD123319 and compared with untreated age-matched controls. Offspring were studied within 24 h of birth. Type I and type III collagen mRNA expression, as well as TGF-β1 mRNA expression, were examined by in situ hybridization. Collagen concentration was determined spectrophotometrically by picrosirius red staining and type I and III collagens were detected by immunoblotting. Results: We found: (1) comparable birth weights in control and PD123319-treated animals, but reduced body weight in newborn losartan-treated animals; (2) compared to untreated animals, type I collagen and TGF-β1 mRNA expression in cardiac tissue were each equally reduced in both losartan and PD123319-treated animals; (3) increased type III collagen mRNA expression in both PD123319- and losartan-treated groups; and (4) a significant decrease in total soluble cardiac collagen concentration in both losartan and PD123319-treated groups, confirmed by attenuated immunoreactivity of type I and III collagens in whole heart extracts by Western blotting. Conclusions: The results of these pharmacologic interventions suggest AngII receptors are expressed in cardiac tissue during gestation, where both AT1 and AT2 receptors are involved in the regulation of type I and III collagen expression and structural protein accumulation. These effects appear to be mediated, in part, by attenuated cardiac TGF-β1 levels. The marked decrease in newborn cardiac collagen content has yet undefined functional consequences.

KEYWORDS Cardiac development; Type I and III collagens; Losartan; TGF-β1


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Physiol. Rev.Home page
M. Paul, A. Poyan Mehr, and R. Kreutz
Physiology of local Renin-Angiotensin systems.
Physiol Rev, July 1, 2006; 86(3): 747 - 803.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
G. Graiani, C. Lagrasta, E. Migliaccio, F. Spillmann, M. Meloni, P. Madeddu, F. Quaini, I. M. Padura, L. Lanfrancone, P. Pelicci, et al.
Genetic Deletion of the p66Shc Adaptor Protein Protects From Angiotensin II-Induced Myocardial Damage
Hypertension, August 1, 2005; 46(2): 433 - 440.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
I. Armando, M. Jezova, A. V. Juorio, J. A. Terron, A. Falcon-Neri, C. Semino-Mora, H. Imboden, and J. M. Saavedra
Estrogen upregulates renal angiotensin II AT2 receptors
Am J Physiol Renal Physiol, November 1, 2002; 283(5): F934 - F943.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. L. Segar, G. B. Dalshaug, K. A. Bedell, O. M. Smith, and T. D. Scholz
Angiotensin II in cardiac pressure-overload hypertrophy in fetal sheep
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2001; 281(6): R2037 - R2047.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.